

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/890,353		07/30/2001	Svetlana Alexadrovna Morenkova	P67002US0	1986
136	7590	10/02/2002		EXAMI	NED
JACOBSO 400 SEVEN SUITE 600		MAN PLLC EET N.W.		WINSTON, RANDALL O	
WASHINGTON, DC 20004				ART UNIT	PAPER NUMBER
				1651	
				DATE MAILED: 10/02/2002	5

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

Applica\_(s

09/890,353

Morenkova

Examiner

Randall Winston

Art Unit **1651** 



		- I and oddross
The	MAILING DATE of this communication appears on ti	ne cover sheet with the correspondence address
THE MAILIN  - Extensions of time mailing date of the seriod for th	ED STATUTORY PERIOD FOR REPLY IS SET TO G DATE OF THIS COMMUNICATION.  The may be available under the provisions of 37 CFR 1.136 (a). In no even his communication.	tutory minimum of thirty (30) days will be considered timely.  Ill expire SIX (6) MONTHS from the mailing date of this communication.
01-4		
1) 🗌 Respo	onsive to communication(s) filed on	·
2a) 🗌 This a	action is <b>FINAL.</b> — — 2b) 🗓 This action	is_non-final.
3) Since	this application is in condition for allowance exc d in accordance with the practice under <i>Ex parte</i>	ent for formal matters, prosecution as to the merits is
Disposition of	Claims	is/are pending in the application.
4) 💢 Claim	(s) <u>1-12</u>	
4a) Of	the above, claim(s)	is/are withdrawn from consideration.
5) Claim	n(s)	is/are allowed.
C) Claim	n(s)	is/are rejected.
6) ☐ Claim	n(s)	is/are objected to.
7) ∐ Clain	n(s)	are subject to restriction and/or election requirement.
		are subject to restriction and/or election requirement.
Application I		
9) ☐ The	specification is objected to by the Examiner.	occopied or h) objected to by the Examiner.
10) 🗌 The	drawing(s) filed on is/are a	accepted or b) objected to by the Examiner.
11)□ The	plicant may not request that any objection to the dra	is: a) approved by the Examiner
	approved, corrected drawings are required in reply to	
	oath or declaration is objected to by the Examina	51.
13) 💢 Ack	er 35 U.S.C. §§ 119 and 120 knowledgement is made of a claim for foreign prid	ority under 35 U.S.C. § 119(a)-(d) or (f).
a) 💢 A	ll b)□ Some* c)□ None of:	A constraint
1. 💢	Certified copies of the priority documents have	been received.
2. □	Certified copies of the priority documents have	been received in Application No
3. [	Copies of the certified copies of the priority do application from the International Burea he attached detailed Office action for a list of the	cuments have been received in this National Stage u (PCT Rule 17.2(a)). certified copies not received.
See ti	knowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
	the translation of the foreign language provisional	application has been received.
a  □   15\□ ^^	knowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachment(	s) of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
	of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Petent Application (PTO-152)
	ation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:

Application/Control Number: 09/890,353

Art Unit: 1651

## **DETAILED ACTION**

## Election/Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-6, drawn to an insulin-containing medicine for peroral use containing insulin and an auxiliary substance.

Group II, claim(s) 7-12, drawn to a method for derivation of insulin-containing medicine for peroral use, including the excretion of erythrocytes from fresh mammal blood etc.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature of Group I's composition which is drawn to an insulin-containing medicine for peroral use containing insulin and an auxiliary substance is mutually exclusive from Group II's method which is drawn to a method for derivation of insulin-containing medicine for peroral use, including the erythrocytes from fresh mammal blood etc.. Thus, the special technical feature of Group II is missing from Group I, and vice-versa and therefore, there is no Unity of Invention between Group I's

Application/Control Number: 09/890,353

Art Unit: 1651

composition and Group II's method (i.e, Group II's method comprises of steps (i.e., of different temperatures and/or time and/or amounts and/or active ingredients) different from of what Group I's composition requires).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication should be directed to Randall Winston, at telephone number (703) 305-0404. The examiner can normally be reached during the hours of 07:30 to 16:00 Eastern Time, Mon-Thursday. If attempts to reach the examiner by telephone are unsuccessful, a message may be left on the voice mail. The fax number for Art Unit 1651 is (703) 308-4242 or 305-3014. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-4743.

row

RandallWinston Examiner, 1651

CHRISTOPHER R. TATE PRIMARY EXAMINER